scispace - formally typeset
Open AccessJournal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TLDR
Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
About
This article is published in Atherosclerosis.The article was published on 2019-09-02 and is currently open access. It has received 2972 citations till now. The article focuses on the topics: Lipid modification & Very low-density lipoprotein.

read more

Citations
More filters

Standards of Medical Care in Diabetes

TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Journal ArticleDOI

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L.J. Visseren, +105 more
Journal Article

Effects of the amount and intensity of exercise on plasma lipoproteins: Editor's comments

TL;DR: The highest amount of weekly exercise, with minimal weight change, had widespread beneficial effects on the lipoprotein profile, seen most clearly with the high amount of high-intensity exercise.
Journal ArticleDOI

Atorvastatin in Patients With Type 2 Diabetes Mellitus Undergoing Hemodialysis

TL;DR: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
References
More filters
Journal ArticleDOI

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).

TL;DR: In this article, the authors assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels in a cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C during a median follow-up of 2 years.
Journal ArticleDOI

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

TL;DR: Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidenceof non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced.
Journal ArticleDOI

Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects.

TL;DR: A moderate substitution of saturated fatty acids with monounsaturated fatty acids has beneficial effects on lipid metabolism also in healthy individuals and reduces both fasting and post-prandial triacylglycerol concentrations but increases LDL cholesterol, irrespective of the type of diet.
Journal ArticleDOI

Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk

TL;DR: This comprehensive, critical review of available data in dyslipidemic subjects indicates that niacin is more efficacious in raising HDL-C than fibrates, whereasniacin and fibrate reduce TG-rich lipoproteins and LDL comparably.
Journal ArticleDOI

An assessment by the Statin Liver Safety Task Force: 2014 update

TL;DR: This panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes, including the value of baseline liver enzymes before initiating statin therapy, and safety of statin use in patients with nonalcoholic fatty liver disease.
Related Papers (5)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more